References
- Alinaghi, F., Tekin, H. G., Burisch, J., Wu, J. J., Thyssen, J. P., Egeberg, A. (2020). Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease: A systematic review and meta-analysis. J. Crohn's Colitis, 14 (3), 351–360.10.1093/ecco-jcc/jjz15231504363
- Ananthakrishnan, A. N. (2015). Epidemiology and risk factors for IBD. Nature Rev. Gastroenterol. Hepatol., 12 (4), 205–217. https://doi.org/10.1038/nrgastro.2015.34.10.1038/nrgastro.2015.3425732745
- Baumgart, D. C., Bernstein, C. N., Abbas, Z., Colombel, J. F., Day, A. S., D'Haens, G., Dotan, I., Goh, K. L., Hibi, T., Kozarek, R. A. et al. (2011). IBD Around the world: Comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010–Inflammatory Bowel Disease Task Force meeting. Inflamm. Bowel Dis., 17 (2), 639–644.10.1002/ibd.2140920725944
- Boehncke, W.-H. (2018). Systemic inflammation and cardiovascular comorbidity in psoriasis patients: Causes and consequences. Front Immunol., 9, 579.10.3389/fimmu.2018.00579589564529675020
- Chapman, T. P., Frias Gomes, C., Louis, E., Colombel, J. F., Satsangi, J. (2020). Withdrawal of 5-aminosalicylates in inflammatory bowel disease. Alim. Pharmacol. Ther., 52 (1), 73–84.10.1111/apt.1577132452591
- Cosnes, J., Gowerrousseau, C., Seksik, P., Cortot, A. (2011). Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology, 140, 1785–1794.10.1053/j.gastro.2011.01.05521530745
- Danese, S., Semeraro, S., Papa, A., Roberto, I., Scaldaferri, F., Fedeli, G., Gasbarrini, G., Gasbarrini, A. (2005). Extraintestinal manifestations in inflammatory bowel disease. World J. Gastroenterol., 11 (46), 7227. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725142/.
- Doherty, G., Katsanos, K. H., Burisch, J., Allez, M., Papamichael, K., Stallmach, A., Mao, R., Berset, I. P., Gisbert, J. P., Sebastian, S., Kierkuś, J. (2018). European Crohn’s and Colitis Organisation topical review on treatment withdrawal [‘exit strategies’] in inflammatory bowel disease. J. Crohn's Colitis, 12 (1), 17–31. https://academic.oup.com/ecco-jcc/article/12/1/17/4060442#107604318.
- Freeman, K., Ryan, R., Parsons, N., Taylor-Phillips, S., Willis, B. H., Clarke, A. (2021). The incidence and prevalence of inflammatory bowel disease in UK primary care: A retrospective cohort study of the IQVIA Medical Research Database. BMC Gastroenterol., 21 (1), 1–7. https://academic.oup.com/jcag/article/2/Supplement_1/S17/5153302?login=true.
- Fu, Y., Lee, C. H., Chi, C. C. (2018). Association of psoriasis with inflammatory bowel disease: A systematic review and meta-analysis. JAMA Dermatology, 154 (12), 1417–1423. DOI: 10.1001/jamadermatol.2018.3631.10.1001/jamadermatol.2018.3631658337030422277
- Gjuladin-Hellon, T., Gordon, M., Iheozor-Ejiofor, Z., Akobeng, A. K. (2019). Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database of Systematic Reviews, (6). https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008414.pub3/full.
- Harbord, M., Annese, V., Vavricka, S. R., Allez, M., Barreiro-de Acosta, M., Boberg, K. M., Burisch, J., De Vos, M., De Vries, A. M., Dick, A. D., Juillerat, P. (2016). The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J. Crohn's Colitis, 10 (3), 239–254. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957476/.
- Hedin, C. R. H., Vavricka, S. R., Stagg, A. J., Schoepfer, A., Raine, T., Puig, L., Pleyer, U., Navarini, A., Van Der Meulen-De Jong, A. E., Maul, J., Katsanos, K. (2019). The pathogenesis of extraintestinal manifestations: Implications for IBD research, diagnosis, and therapy. J. Crohn's Colitis, 13 (5), 541–554.10.1093/ecco-jcc/jjy19130445584
- Kaine, J., Song, X., Kim, G., Hur, P., Palmer, J. B. (2018). Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using US administrative claims data. J. Manag. Care Spec. Pharm., 24, 1–11.
- Kirchgesner, J., Beaugerie, L., Carrat, F., Andersen, N. N., Jess, T., Schwarzinger, M. (2017). Increased risk of acute arterial events in young patients and severely active IBD: A nationwide French cohort study. Gut, 67, 1261–1268.10.1136/gutjnl-2017-31401528647686
- Kosmidou, M., Katsanos, A. H., Katsanos, K. H., Kyritsis, A. P., Tsivgpoulis, G., Christodoulou, D., Giannopoulos, S. (2017). Multiple sclerosis and inflammatory bowel diseases: A systematic review and meta-analysis. J. Neurol., 264, 254–259.10.1007/s00415-016-8340-827878439
- Krustins, E., Pokrotnieks, J. (2014). IBD prevalence in Baltic states or just a guessing game? J. Crohn's Colitis, 8 (8), 902–902.10.1016/j.crohns.2014.01.01524491517
- Lakatos, L., Pandur, T., David, G., Balogh, Z., Kuronya, P., Tollas, A., Laszlo, L. (2003). Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: Results of a 25-year follow-up study. World J. Gastroenterol., 9, 2300–2307.10.3748/wjg.v9.i10.2300465648214562397
- Lin, J.-C., Lin, C.-S., Hsu, C.-W., Lin, C.-L., Kao, C.-H. (2016). Association between Parkinson’s disease and inflammatory bowel disease. Inflamm. Bowel Dis., 22, 1049–1055.10.1097/MIB.000000000000073526919462
- Mahid, S. S., Minor, K. S., Soto, R. E., Hornung, C. A., Galandiuk, S. (2006). Smoking and inflammatory bowel disease: A meta-analysis. Mayo Clin. Proc., 81, 1462–1471.10.4065/81.11.146217120402
- McAuliffe, M. E., Lanes, S., Leach, T., Parikh, A., Faich, G., Porter, J., Holick, C., Esposito, D., Zhao, Y., Fox, I. (2015). Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database. Curr. Med. Res. Opin., 31 (9), 1655–1664. https://www.tandfonline.com/doi/abs/10.1185/03007995.2015.1065242?journalCode=icmo20.
- Michalek, I. M., Loring, B., John, S. M. (2017). A systematic review of worldwide epidemiology of psoriasis. J. Eur. Acad. Dermatol. Venereol., 31 (2), 205–212. https://onlinelibrary.wiley.com/doi/10.1111/jdv.13854.
- Mirzajanova, I., Purviņa, S., Pokrotnieks, J. (2020). Incidence and prevalence of Crohn’s disease and ulerative colitis (2013–2017) based on the Latvian Nationwide Medicines Reimbursement Database. In: Proc. Latvian Acad. Sci. Section B., 74 (2), 138–143. https://sciendo.com/pdf/10.2478/prolas-2020-0022.10.2478/prolas-2020-0022
- Molodecky, N. A., Soon, I. S., Rabi, D. M., Ghali, W. A., Ferris, M., Chernoff, G., Benchimol, E. I., Panaccione, R., Ghosh, S., Barkema, H. W., Kaplan, G. G. (2012). Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology, 142, 46–54. e42; quiz e30.10.1053/j.gastro.2011.10.00122001864
- Nacionālais veselības dienests (2021). Kompensējamie medikamenti. Normatīvo aktu sistēma [National Health Service. Reimbursable drugs. Laws and regulations]. www.vmnvd.gov.lv
- OECD (2021). Health at a Glance 2021: OECD Indicators. OECD Publishing, Paris. https://doi.org/10.1787/ae3016b9-en.10.1787/ae3016b9-en
- OECD/European Observatory on Health Systems and Policies (2021). Latvia: Country Health Profile 2021. State of Health in the EU. OECD Publishing, Paris. https://doi.org/10.1787/919f55f0-en.10.1787/919f55f0-en
- Papa, A., Scaldaferri, F., Danese, S., Guglielmo, S., Roberto, I., Bonizzi, M., Mocci, G., Felice, C., Ricci, C., Andrisani, G., et al. (2008). Vascular involvement in inflammatory bowel disease: Pathogenesis and clinical aspects. Dig. Dis., 26, 149–155.10.1159/00011677318431065
- Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J. C., Saunders, L. D., Beck, C. A., Feasby, T. E., Ghali, W. A. (2005). Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med. Care, 1130–1139. https://journals.lww.com/lww-medicalcare/Abstract/2005/11000/Coding_Algorithms_for_Defining_Comorbidities_in.10.aspx.
- Rogler, G., Singh, A., Kavanaugh, A., Rubin, D. T. (2021). Extraintestinal manifestations of inflammatory bowel disease: Current concepts, treatment, and implications for disease management. Gastroenterology, 161 (4), 1118–1132. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564770/.
- Román, A. L. S., Muñoz, F. (2011). Comorbidity in inflammatory bowel disease. World J. Gastroenterol., 17, 2723–2733.10.3748/wjg.v17.i22.2723312226021734780
- Ruel, J., Ruane, D., Mehandru, S., Gower-Rousseau, C., Colombel, J. F. (2014). IBD across the age spectrum: Is it the same disease? Nat. Rev. Gastroenterol. Hepatol., 11, 88–98.10.1038/nrgastro.2013.24024345891
- Schüle, S., Rossel, J. B., Frey, D.,Biedermann, L., Scharl, M., Zeitz, J., Freitras-Queiroz, N., Kuntzen, T., Greuter, T. (2017). Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study. Medicine, 96, e6788.10.1097/MD.0000000000006788545969628562531
- Slimību profilakses un kontroles centrs (2019). Smēķēšanas izplatība un sekas Latvijā 2018. gadā. 7. izdevums [Expansion and Consequences of Smoking in Latvia, 2018. 7th edn.]. Rīga, 2019. 14 pp. (in Latvian). https://www.spkc.gov.lv/lv/zinojumi/tematiskais-zinojums-smekesanas-izplatiba-un-sekas-latvija-2018.gada-7.-izdevums.pdf.
- Strober, B., Karki, C., Mason, M., Guo, N., Holmgren, S. H., Greenberg, J. D., Lebwohl, M. (2018). Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry. J. Amer. Acad. Dermatol., 78 (2), 323–332. https://www.sciencedirect.com/science/article/pii/S019096221732538010.1016/j.jaad.2017.10.01229051036
- Su, C. G., Judge, T. A., Lichtenstein, G. R. (2002). Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol. Clin. North Amer., 31, 307–327.10.1016/S0889-8553(01)00019-X12122740
- Sy, A., Khalidi, N., Dehghan, N., Barra, L., Carette, S., Cuthbertson, D., Hoffman, G. S., Koening, C. L., Langford, C. A., McAlear, C., Moreland, L. (2016). Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. In: Seminars in Arthritis and Rheumatism, 45 (4), 475–482. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982464/.
- Turesson, C. (2016). Comorbidity in rheumatoid arthritis. Swiss Med. Wkly, 146, w14290.10.4414/smw.2016.1429027045333
- Vadstrup, K., Alulis, S., Borsi, A., Jørgensen, T. R., Nielsen, A., Munkholm, P., Qvist, N. (2020). Extraintestinal manifestations and other comorbidities in ulcerative colitis and Crohn Disease: A Danish Nationwide Registry Study 2003–2016. Crohn's Colitis 360, 2 (3), DOI: 10.1093/crocol/otaa070. https://academic.oup.com/crohnscolitis360/article/2/3/otaa070/5896668?login=true.
- Van Limbergen, J., Radford-Smith, G., Satsangi, J. (2014). Advances in IBD genetics. Nat. Rev. Gastroenterol. Hepatol., 11, 372–385.10.1038/nrgastro.2014.2724614343
- Van Onna, M., Boonen, A. (2016). The challenging interplay between rheumatoid arthritis, ageing and comorbidities. BMC Musculoskel. Disord., 17, 184.10.1186/s12891-016-1038-3484536327118031
- Vavricka, S. R., Schoepfer, A., Scharl, M., Lakatos, P. L., Navarini, A., Rogler, G. (2015). Extraintestinal manifestations of inflammatory bowel disease. Inflamm. Bowel Dis., 21 (8), 1982–1992. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511685/.
- Wagtmans, M. J., Verspaget, H. W., Lamers, C. B. van Hogezand, R. A. (2001). Gender-related differences in the clinical course of Crohn’s disease. Amer. J. Gastroenterol., 96, 1541–1546.10.1111/j.1572-0241.2001.03755.x11374696
- Yarur, A. J., Deshpande, A. R., Pechman, D. M., Tamariz, L., Abreu, M. T., Sussman, D. A. (2011). Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Amer. J. Gastroenterol., 106, 741–747.10.1038/ajg.2011.6321386828